The total ctDNA tumor burden was reduced (total MAF from 3.9% to 2.3%), consistent with the presence of a subset of tumor cells harboring HER2 mutations and reflecting the partial clinical response observed in the patient. The gene discussed is ERBB2; the disease is neoplasm.